In addition, lncRNA (Liu et al., 2021a), miRNA, histone modification regulatory proteins, and intracellular small-molecule metabolites are also involved in the regulatory process of RNA m6A modification, which further enables RNA m6A modulation of the regulation of drug resistance in glioma. This evidence concerns the gene PROS1 and central nervous system cancer.